Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what executives described as positive Phase 3 results and outlining an expanded commercial plan supported by a recent $230 million financing.